Legacy Healthcare Launches Phase 3 Trial for Alopecia Areata Treatment Cinainu Following FDA Approval Legacy Healthcare is set to advance Cinainu, a topical solution for alopecia areata, into an international Phase 3 trial after receiving FDA clearance.

Legacy Healthcare Launches Phase 3 Trial for Alopecia Areata Treatment Cinainu Following FDA Approval #United_States #Alopecia_Areata #Epalinges #Cinainu #Legacy_Healthcare

Legacy Healthcare Advances with Cinainu for Alopecia Areata After PMDA Approval Legacy Healthcare received positive feedback from Japan's PMDA for Cinainu, a treatment for alopecia areata in children and adults, indicating progress in regulatory phases.

Legacy Healthcare Advances with Cinainu for Alopecia Areata After PMDA Approval #Japan #Tokyo #Alopecia_Areata #Cinainu #Legacy_Healthcare

Legacy Healthcare Announces Promising Results for New Alopecia Areata Treatment in British Journal of Dermatology Legacy Healthcare's Cinainu shows significant promise in treating moderate to severe alopecia areata, with positive Phase 2/3 trial results published in the British Journal of Dermatology.

Legacy Healthcare Announces Promising Results for New Alopecia Areata Treatment in British Journal of Dermatology #Switzerland #Lausanne #Alopecia #Cinainu #Legacy_Healthcare